The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2023 | The role and clinical use of TPO receptor agonists in the treatment of ITP
David Kuter, MD, DPhil, Massachusetts General Hospital, Boston, MA, discusses the role and clinical use of thrombopoietin (TPO) receptor agonists in the treatment of immune thrombocytopenia (ITP). Prof. Kuter highlights four currently available agents, three oral (avatrombopag, eltrombopag, and hetrombopag), and one subcutaneous (romiplostim), which have demonstrated high response rates and minimal side effects in patients with newly diagnosed ITP. Accessibility to these agents, however, remains an obstacle to widespread use. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research: Alnylam, Biocryst, Novartis, Rigel, Sanofi (Principia), Takeda (Bioverativ), UCB
Consulting: AIRx, Alexion (Syntimmune), Alnylam, Alpine, Amgen, Argenx, BioCryst, Bristol Myers Squibb (BMS), Caremark, Cellularity, Cellphire, Chugai, CRICO, Daiichi Sankyo, Dianthus, Electra Therapeutics, Fuji, Hemopure, Hengrui. Immunovant, Incyte, Inmagenebio, Kezar, Kyowa-Kirin, Merck Sharp Dohme, Momenta, Novartis, Nuvig, Pfizer, Platelet Biogenesis, Platelet Disorder Support Association, Protagonist, Rigel, Sanofi (Bioveratif), Sanofi (Principia). Sanofi (Genzyme), Sobi (Dova), Takeda, UCB, Up-To-Date, Zafgen
Stock ownership: Rubius
